<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02780778</url>
  </required_header>
  <id_info>
    <org_study_id>AHEAD-HBL0001</org_study_id>
    <nct_id>NCT02780778</nct_id>
  </id_info>
  <brief_title>Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer</brief_title>
  <official_title>Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase II, Open-label, single arm, exploratory study is to evaluate the
      efficacy and the safety of Apatinib（500mg/d）with docetaxel (60 mg/m²) in advanced
      Non-squamous Non-small cell lung cancer after failure of first line chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>1 Day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective remission rate</measure>
    <time_frame>1 Day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>1 Day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>1 Day</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib：500 mg，po，qd； Docetaxel：60mg/m²，vein input 1hour，every 3w</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Targeted therapy Apatinib：500 mg，po，qd</description>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>YN968D1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>chemotherapy Docetaxel：60mg/m²，vein input 1hour，every 3w</description>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 and ≤ 75 years of age

          -  Histologically or cytologic confirmed advanced non-squamous and non-small cell lung
             cancer.

          -  EGFR mutation testing negative of sensitive mutations

          -  At least one measurable lesion which has not received radiotherapy (larger than 10 mm
             in diameter by spiral CT scan)

          -  Have failed for 1 lines of chemotherapy

          -  ECOG performance scale 0 - 1.

          -  Life expectancy of more than 3 months.

          -  Duration from the last therapy is more than 6 weeks for nitroso or mitomycin

          -  More than 4 weeks after operation or radiotherapy

          -  More than 4 weeks for cytotoxic agents

          -  Adequate hepatic, renal, heart, and hematologic functions (hemoglobin ≥ 90g/L,
             platelets ≥ 80×10^9/L, neutrophils ≥ 1.5×10^9/L, total bilirubin within 1.25×the upper
             limit of normal(ULN), and serum transaminase≤2.5×the ULN (If liver metastases, serum
             transaminase≤5×the ULN), serum creatine ≤ 1.5 x ULN, creatinine clearance rate ≥
             50ml/min,

          -  Signed and dated informed consent.Willingness and ability to comply with scheduled
             visits, treatment plans, laboratory tests, and other study procedure.

        Exclusion Criteria:

          -  Received more than one kind of chemotherapy regimens

          -  NSCLC received other VEGFR inhibitors (except beacizumab) or docetaxel chemotherapy

          -  Existing therapy related toxicity of prior chemotherapy and/or radiation therapy

          -  Intercurrence with one of the following: hypertension, coronary artery disease,
             arrhythmia and heart failure

          -  Any factors that influence the usage of oral administration

          -  The center of the tumor invaded local large blood vessels

          -  Within 4 weeks before the first use of drugs, occurs pulmonary hemorrhage (≥ CTCAE
             class 2) or other parts' hemorrhage (≥ CTCAE class 3).

          -  Within 6 months before the first treatment occurs artery / venous thromboembolic
             events, such as cerebral vascular accident (including transient ischemic attack), deep
             vein thrombosis and pulmonary embolism, etc.

          -  Less than 4 weeks from the last clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhanyu Pan, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Clinical Research Center for Cancer of China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhanyu Pan, Master</last_name>
    <phone>86-13752570372</phone>
    <email>wangcongalex@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhanyu Pan, Master</last_name>
      <phone>86-13752570372</phone>
      <email>wangcongalex@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2016</study_first_submitted>
  <study_first_submitted_qc>May 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2016</study_first_posted>
  <last_update_submitted>May 19, 2016</last_update_submitted>
  <last_update_submitted_qc>May 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

